BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

PolyPid Ltd. Raises $2 Million in Second Round of Financing


1/24/2012 9:52:40 AM

Petach Tikva, Israel, January 23, 2012. PolyPid Ltd., a developer of innovative drug carriers, today announced that it has raised $2 million in a second round of financing from existing and new investors, at a company post-money valuation of $10 million.

In 2010, PolyPid raised $1.4 million from private investors in a first round of financing.

PolyPid's flagship platform, PolyPid, is a new, groundbreaking family of drug carriers, based on fusion between two known delivery platforms: polymers and lipid-based systems. PolyPid enables long-lasting and controlled release of Active Pharmaceutical Ingredients (APIs). The revolutionary, patented platform can be tailored to almost any API – small molecules, peptides, proteins and nucleic acid. The formulations can be pre-programmed in order to achieve the desired release rate of the APIs and the optimal duration, which can last up to several months.

The PolyPid platform's first product is BonyPidTM, a biodegradable bone void filler that is nano-coated with a PolyPid biodegradable formulation. The coating gradually releases one or more selected antibiotics into its surroundings. Subsequently, the bone void filler scaffold remains and supports bone recovery.

“The money raised will be used to further invest in research and development, bringing additional products to the market, and to conduct a clinical trial that will treat patients with open fractures," said Dr. Noam Emanuel, PolyPid’s Chief Technology Officer.

About PolyPid

Founded in 2008 and located in Israel, PolyPid is a privately held, development stage company that has developed a platform technology for the healthcare industry that enables a controlled and prolonged release of any active pharmaceutical ingredients (API). PolyPid’s technology combines polymers and lipids, enabling small-and-large API entrapment in degradation and hydration protected environments, regardless of their chemical or physical characteristics. PolyPid allows the release of the API from the reservoir at pre-determined rates of up to several months, with a constant release rate (zero-order kinetics). The flexibility of this innovative technology enables local administration of compounds across numerous therapeutic classes for several applications. PolyPid Ltd. is owned by the founders, private investors and Xenia Venture Capital. For more information about PolyPid, visit www.polypid.com

Contact:

David Kanaan

Kanaan Public Relations

Tel.: +972-54-4255307

e-mail: David@KanaanPR.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->